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The RGA Committee met on October 29-30, 2012,
in Crystal City, VA. The Committee corresponded via
e-mail throughout the year, and had a conference call on
June 13, 2013. The charge for the RGACommittee was to
develop strategies on how to get our members to the right
tables and at the right time for advancing pharmacy re-
search and graduate education.
The Committee members had examined the NIH
Biomedical ResearchWorkforceWorking Group Report,
NIH Diversity in the Biomedical Research Workforce
report, andWays toManageNIHGrants fromNIHOffice
of Extramural Grants.
The following topics were considered and discussed.
Some action plans are recommended for implementation.
GRADUATE STUDENT EDUCATION:
MEETING THE NEEDS OF A RAPIDLY
CHANGING MARKET
The academy needs more Pharm.D.s to be ade-
quately trained and engaged in pharmacy research. We
also need more faculty research scientists, who have a
pharmacy background.
Possible Action Plans
d Bring in more high school, undergraduate, and
Pharm.D. students into pharmacy/pharmaceutical re-
search teams.
d Increase contact and interaction between profes-
sional and graduate students.
d Identify and attract more scholarships for students in
clinical sciences (e.g., pharmacy scholars).
d Clearly define differences in pharmacy disciplines
as they relate to the ideal pool of graduate students.
d Develop marketing strategy to attract more U.S.
trained students and Pharm.D. applicants to be inter-
ested in graduate school education. (VL is working on
the PharmCAS concept for graduate programs)
d Train more leaders and mentors (e.g., ARFP), who
will assume a role in enhancing their graduate de-
gree programs.
The Committee agreed that it is time to transform
graduate education (M.S. and Ph.D.) in pharmacy and
pharmaceutical sciences.
Possible Action Plans
d This will be a topic of discussion for the Academic
Research Fellows Program. (VL is working on this
effort)
d Same discussion should occur with associate deans
for research and graduate studies. (VL will work
with this group). Views will be shared with Phar-
macy Deans Research Group in January as well
(RB).
d Following any input received from the above groups,
we should articulate the need and identify the mech-
anisms for graduate training transformation.
d Emphasize interprofessional and interdisciplinary
training rather than silo training approaches.
d Define and develop a set of required competency-
based skills for all graduates to acquire (these days
so many soft skills are important for career success,
an integrated curriculum should include those skills
in communication, writing, adaptability, etc.). Since
there is no movement towards accreditation of grad-
uate programs, we should perhaps look into a CAPE-
like taskforce for graduate education.
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d Use the NIH Workforce Document as a starting
point to create a process that may lead to a white
paper; seek input from key stakeholders (e.g.
Pharma, FDA).
INDUSTRIAL AND FEDERAL RESEARCH
FUNDING
There has been a continuous evolution of the phar-
maceutical industry. The industry is mostly interested in
recruiting our graduates, but few are interested in invest-
ing in graduate training programs.Only a small number of
schools still have ties to industry and receive graduate
training grants from them.
Possible Action Plans
d We should explore and identify unique company
needs and opportunities, and seek out our alumni who
are currently residing at pharmaceutical companies to
advocate and assist in the development of sustainable
relationships.
NIH funding has become extremely competitive.
This situation affects not only junior faculty, but also
faculty at all ranks. Furthermore, NIH plans to reevalu-
ate its fundingmodel including reducing salary recovery
and F&A.
Possible Action Plans
d A good mentoring program for junior, mid-career,
and senior faculty might help funding sustainability.
Providing our faculty with critical internal or exter-
nal grant reviews prior to grant submission may
enhance the quality and competitiveness of their
submissions. We believe that the reviewers’ time
and effort should be financially compensated for this
service.
d Institutional bridge funding is becoming increasingly
more important in this current climate of single digit
percentile pay-lines at the NIH. Institutions and
Schools/Colleges will need to plan more strategi-
cally in order to fill critical funding gaps in support
of its faculty.
d Faculty should be encouraged to use the sab-
batical opportunity to retool or engage in new
areas of contemporary research as part of faculty
development.
d Faculty establishment of laboratories in a foreign
country should be carefully studied within each in-
stitution to assess thoroughly conflicts of interest
and commitment as well as impact and value to
the School/College.
d Faculty mentoring is needed to better understand
the funding areas and mechanisms such as from
NCATS, COBRE, and other similar programs.
d Institutions need to reevaluate teaching and ser-
vice loads for research-intensive tenured/tenure
track faculty for them to better compete for NIH
funding.
d We should consider all kinds of funding sources
including non-federal agencies (VL is working on
providing information on other funding opportu-
nities).
d Institutional timeline and criteria for promotion and
tenure may need to be reevaluated.
THE EVOLUTION OF THE RESEARCH-
INTENSIVE UNIVERSITY: POSITIONING
PHARMACY IN THIS NEW ENVIRONMENT
It is well recognized that almost 35% of federal
funding goes to 25 institutions and each of these insti-
tutions will likely continue to strengthen their compet-
itive position.This trend is not likely to change and
pharmacy needs to strategically position itself for this
new reality.
Possible Action Plans
d Schools should consider collaborations with other
schools and universities for the purpose of en-
hancing mutual competitiveness in specific, tar-
geted areas.
d Inter-institutional collaborations may be worthwhile
particularly with graduate education; distance edu-
cation may change everything.
d Large clinical trials are multi-institutional – schools
should build on these opportunities.
d Academic Research Fellows could complement
each other to create more competitive projects
and consortia.
POLITICAL AND FEDERAL FUNDING
ADVOCACY: WHAT SHOULD/CAN OUR
ACADEMY DO TO ENSURE PHARMACY
SCHOOLS/COLLEGES ARE WELL-
POSITIONED FOR RESEARCH AND
GRADUATE EDUCATION SUPPORT?
Possible Action Plans
d Develop consortium and agreements with partner
organizations (e.g., AAPS, ACCP, ACCM, ISPOR,
JCCP) that have high presence of pharmacists
and pharmaceutical scientists for the purpose of
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creating a single voice for pharmaceutical sciences
research advocacy.
d Focus on a single strategy in translational research
(i.e., NCATS, CTSAs).
d Identify additional partners (e.g., FDA, NPC,
ASPET [Pharmacology], SOT, Critical Path
Institute).
d AACP President, CEO and CSO will identify and
initiate conversations with counterparts of other or-
ganizations.
d Emphasize the big picture of our research enterprise
(i.e. our strength is making drug discovery more
efficient).
d If not successful, AACP must reevaluate its strategy.
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